Unknown

Dataset Information

0

Berberine ameliorates chronic kidney disease through inhibiting the production of gut-derived uremic toxins in the gut microbiota


ABSTRACT: At present, clinical interventions for chronic kidney disease are very limited, and most patients rely on dialysis to sustain their lives for a long time. However, studies on the gut–kidney axis have shown that the gut microbiota is a potentially effective target for correcting or controlling chronic kidney disease. This study showed that berberine, a natural drug with low oral availability, significantly ameliorated chronic kidney disease by altering the composition of the gut microbiota and inhibiting the production of gut-derived uremic toxins, including p-cresol. Furthermore, berberine reduced the content of p-cresol sulfate in plasma mainly by lowering the abundance of g_Clostridium_sensu_stricto_1 and inhibiting the tyrosine–p-cresol pathway of the intestinal flora. Meanwhile, berberine increased the butyric acid producing bacteria and the butyric acid content in feces, while decreased the renal toxic trimethylamine N-oxide. These findings suggest that berberine may be a therapeutic drug with significant potential to ameliorate chronic kidney disease through the gut–kidney axis. Graphical abstract Berberine ameliorates chronic kidney disease through the gut–kidney axis by regulating the metabolism of nephrotoxins such as p-cresol by the gut microbiota.Image 1

SUBMITTER:  

PROVIDER: S-EPMC10149897 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8745165 | biostudies-literature
| S-EPMC9664568 | biostudies-literature
| S-EPMC4951226 | biostudies-literature
| S-EPMC11683462 | biostudies-literature
| S-EPMC8625482 | biostudies-literature
| S-EPMC4886219 | biostudies-literature
| S-EPMC8494360 | biostudies-literature
| S-EPMC7995407 | biostudies-literature
| S-EPMC8545797 | biostudies-literature
| S-EPMC7922022 | biostudies-literature